BRCA1 and breast cancer: Platinum agents, such as cisplatin and carboplatin, and poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi), such as olaparib and niraparib, have demonstrated efficacy for the treatment of BRCA1-mutated BC in clinical trials in both early and advanced stages [155,157].